氘可来昔替尼(Deucravacitinib)能治疗所有类型的银屑病吗？

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

氘可来昔替尼(Deucravacitinib)不能治疗所有类型的银屑病。

There are many types of psoriasis, such as psoriasis vulgaris, arthropathic psoriasis, erythrodermic psoriasis, plaque psoriasis, etc. It is suitable for the treatment of moderate to severe plaque psoriasis that is suitable for full systemic treatment or phototherapy, but it cannot treat all types of psoriasis.

Why Deucravacitinib cannot treat all types of psoriasis

Psoriasis is a complex, multi-type skin disease with different types and severity, and Deucravacitinib is only suitable for the treatment of adults with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy, and cannot treat all types of psoriasis.对于其他类型的银屑病，氘可来昔替尼可能并不适用，可能需要选择其他药物或治疗方案。 For example, vitamin A acid, glucocorticoids, etc.

Types of psoriasis

1. Psoriasis vulgaris: The skin lesions are well-defined red plaques or infiltrative erythema, covered with a thick layer of silver-white scales.部位不同，形态多样，好发于头皮、四肢伸侧及骶尾部。

2、点滴型银屑病：开始表现谷粒大小丘疹，可发展成斑块，多见于躯干部位。

3. Arthropathic psoriasis: In addition to psoriatic skin lesions, symptoms of rheumatoid arthritis may also occur.

4. Erythrodermic psoriasis: Flushing appears at the initial site of the original silver eyebrow skin lesion, rapidly expanding into large areas, and finally diffuse flushing infiltration appears throughout the body.

5、脓疱型银屑病：可分为泛发性脓疱病、掌跖脓疱病、连续性肢端皮炎等。 The itching or tingling sensation on the skin at the onset of the rash will soon appear in groups on the flushed skin surface, which will resolve on its own after a few days or weeks. The whole body will become erythematous and desquamated, becoming erythroderma.

Deucravacitinib

Deucravacitinib is a first-in-class, highly selective oral tyrosine kinase 2 (TYK2) inhibitor that acts through an allosteric mechanism, binding to the catalytically inactive pseudokinase regulatory domain of TYK2 and stabilizing the inhibitory interaction between the regulatory and catalytic domains.

Deucravacitinib was developed by Bristol Myers Squibb and is used to treat a variety of immune-mediated diseases, including psoriasis and psoriatic arthritis. 2022年9月9日，首次在美国获批，用于治疗患有中度至重度斑块型银屑病的成年人。

Therapeutic efficacy of deuterated colexitinib

Deuterated colexitinib was evaluated compared with placebo and apremilast in two 52-week Phase 3 trials in 1,688 patients with moderate to severe psoriasis.

At Week 16, more than 50% of patients receiving deuterated colexitinib achieved PASI 75, significantly better than placebo and apremilast. These results improved through Week 24 and were maintained through Week 52, at which time more than 65% of patients achieved PASI 75.还报告了症状改善，对瘙痒有更大的改善。

氘可来昔替尼耐受性良好且安全。没有严重感染、血栓栓塞事件或实验室异常的报告。在长达2年的时间里，报告了持续的疗效和一致的。

对于中重度银屑病患者，氘可来昔替尼有潜力成为一种安全、有效且耐受性良好的治疗方法。